Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis.
about
Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease.Evidence-based clinical practice guidelines for inflammatory bowel disease.The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.
P2860
Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Mesalamine, but Not Sulfasalaz ...... atic Review and Meta-analysis.
@en
type
label
Mesalamine, but Not Sulfasalaz ...... atic Review and Meta-analysis.
@en
prefLabel
Mesalamine, but Not Sulfasalaz ...... atic Review and Meta-analysis.
@en
P2093
P2860
P1476
Mesalamine, but Not Sulfasalaz ...... atic Review and Meta-analysis.
@en
P2093
Alan C Moss
Anthony OʼConnor
Christopher D Packey
Mona Akbari
P2860
P304
P356
10.1097/MIB.0000000000000540
P577
2015-08-20T00:00:00Z